Investigation Path - DNA Integrity Project

📋

What is the Application Integrity Policy?

FDA's most powerful tool for investigating regulatory fraud

Historical Background

The Application Integrity Policy (AIP) was established by FDA in 1991 following the Generic Drug Scandal, when multiple pharmaceutical companies submitted fraudulent data and bribed FDA officials. Codified in the Federal Register (56 FR 46191, September 10, 1991), the AIP provides a framework for investigating data integrity violations in drug applications.

AIP Authority and Powers

When invoked, FDA gains extraordinary powers:

⚡

Immediate Actions: Halt pending applications, suspend reviews, and demand immediate access to all raw data and source documents

🔍

Investigatory Powers: Conduct comprehensive audits of trial sites, manufacturing facilities, and laboratories; interview all personnel; require complete documentation including internal communications

⚖️

Remedial Authority: Withdraw product approvals, refuse new approvals, require re-submission with independent verification, impose civil penalties, refer for criminal prosecution

🚫

Debarment Authority: Under 21 U.S.C. § 335a, permanently bar individuals or companies convicted of felonies or engaged in fraud from participating in drug applications

ℹ️ For Pfizer's COVID-19 vaccine, an AIP investigation would require 6-9 months given the program's complexity, number of trial sites, novel mRNA technology, and data volume.

📊

7-Phase Investigation Process

Comprehensive timeline from invocation to regulatory action

Preliminary Assessment

30-60 days

Review allegations and evidence to determine if full AIP invocation is warranted. Evaluate credibility of claims, identify scope of potential violations, and assess impact on public health.

Formal Invocation

Immediate

Notify sponsor of AIP invocation, place all pending applications on hold, demand immediate evidence preservation, conduct surprise inspections of facilities, and issue document retention orders.

Site Audits

3-6 months

Inspect all clinical trial sites involved in C4591001. Verify source documents against regulatory submissions. Interview investigators, coordinators, and staff. Review audit trails and electronic records.

Manufacturing Investigations

2-4 months

Inspect production facilities for Process 1 and Process 2 manufacturing. Review batch records, quality control data, and contamination testing. Assess DNA contamination levels and SV40 sequence documentation.

Data Integrity Analysis

3-6 months

Independent re-analysis of all clinical trial data and statistical methods. Forensic examination of databases. Verification of randomization sequences. Analysis of missing subject records and dataset discrepancies.

Findings Report

60-90 days

Compile comprehensive report categorizing violations by severity and impact. Document evidence chain for each finding. Allow sponsor opportunity to respond. Prepare recommendations for regulatory action.

Regulatory Action

0-9 months

Implement appropriate regulatory actions based on findings: withdrawal of product approvals, civil money penalties, referral to DOJ for criminal prosecution, debarment of responsible individuals or entities.

🎯

Investigation Scope

Comprehensive examination across all five violation categories

📊

Data Audit

Complete forensic examination of all clinical trial databases. Verification of randomization sequences. Analysis of 301 missing subject records.

🏭

Manufacturing Inspections

FDA Form 483 inspections of all facilities involved in Process 1 and Process 2 manufacturing. Review of batch records and QC data.

💻

Digital Forensics

Examination of electronic records and communication systems for evidence of data manipulation, timeline of plasmid map edits.

👥

Witness Interviews

Testimony from clinical investigators, Pfizer employees, BioNTech personnel, FDA review staff, and whistleblowers.

📋

Regulatory Review

Assessment of FDA's handling of applications. Determination of whether agency personnel were aware of classification bypass.

🧬

Laboratory Testing

Independent verification of DNA contamination levels. SV40 sequence analysis. Assessment of qPCR methodology accuracy.

⚖️

Potential Outcomes

Range of regulatory responses based on investigation findings

✅

Best Case

Concerns were misunderstandings or misinterpretations. FDA's original determinations were sound. Investigation restores public confidence in regulatory process and vaccine safety.

⚠️

Intermediate

Specific violations identified but fundamental safety/efficacy conclusions remain valid. Supplemental studies, enhanced monitoring, or labeling updates required while product remains available.

🚨

Serious Violations

Systematic data integrity problems confirmed. Approval withdrawal, restricted use authorization, or market withdrawal pending resolution of safety concerns and corrective actions.

⚖️

Criminal Fraud

Intentional fraud or false statements proven. Department of Justice prosecution under 18 U.S.C. § 1001 and 21 U.S.C. § 333. Substantial fines, imprisonment, and permanent debarment.

⚡

Immediate Actions Requested

What must happen now to preserve evidence and begin investigation

Invoke AIP on all Pfizer/BioNTech COVID-19 vaccine applications including EUA, BLA 125742, and all supplemental applications

Defer Scientific Review of pending applications pending completion of validity assessment

Issue Preservation Notices for all documents and electronic records related to C4591001 databases, manufacturing records, mortality data, regulatory communications, and plasmid maps

Coordinate with OCI (Office of Criminal Investigations) regarding potential criminal referrals to Department of Justice

Evidence Preservation Requirements

Immediate preservation notices must be issued for:

📁

Clinical trial C4591001 databases and all audit trails

🏭

Manufacturing facility records for Process 1 and Process 2

💀

Communications regarding mortality data (Subjects 11141050 and 11201050)

📝

Regulatory submissions and internal discussions regarding product classification

🧬

Plasmid maps (all versions) and DNA contamination testing data

📧

Communications with FDA regarding advisory committee assignments

The Time for Action is Now

Immediate AIP invocation is necessary to preserve remaining evidence, conduct comprehensive validity assessments, ensure regulatory oversight proportionate to product risks, and restore public confidence in regulatory decision-making.